Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage

Authors not listed

Neuromed IRCCS · 2017

Abstract

A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Anonymous. (2017). Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage. <em>Neuromed IRCCS</em>. https://clinicaltrials.gov/study/NCT03217396
Vancouver
Anonymous. Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage. Neuromed IRCCS. 2017.
BibTeX
@misc{anon2017Identi, title = {Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage}, author = {Anonymous}, journal = {Neuromed IRCCS}, year = {2017}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings